Is lipid control necessary in hemodialysis patients?

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue SUPPL. 1, 2009, Pages

  Cheung, Alfred K ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL; EZETIMIBE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB;

ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DRUG EFFICACY; DYSLIPIDEMIA; HEART INFARCTION; HEART PROTECTION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; MONOTHERAPY; PERITONEAL DIALYSIS; PRIMARY PREVENTION; RENAL PROTECTION; RISK FACTOR; STROKE; UREMIA;

ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY FAILURE, CHRONIC; LIPIDS; PRACTICE GUIDELINES AS TOPIC; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; UREMIA;

EID: 73849121142     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04780709     Document Type: Conference Paper

References (51)

1. Lowrie EG, Lew NL: Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15: 458-482, 1990
2. Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D: Serum cholesterol, blood pressure, and mortality: Implications from a cohort of 361,662 men. Lancet 2: 933-936, 1986
3. Law MR, Wald NJ, Rudnicka AR: Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. BMJ 326: 1423-1427, 2003
4. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R: Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267-1278, 2005
5. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E: Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: A PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 46: 1411-1416, 2005
6. Muntner P, He J, Astor BC, Folsom AR, Coresh J: Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: Results from the Atherosclerosis Risk in Communities study. J Am Soc Nephrol 16: 529-538, 2005
7. Williams ME, Lacson E Jr, Teng M, Ofsthun N, Lazarus JM: Hemodialyzed type I and type II diabetic patients in the US: Characteristics, glycemic control, and survival. Kidney Int 70: 1503-1509, 2006
8. Zager PG, Nikolic J, Brown RH, Campbell MA, Hunt WC, Peterson D, Van Stone J, Levey A, Meyer KB, Klag MJ, Johnson HK, Clark E, Sadler JH, Teredesai P: "U" curve association of blood pressure and mortality in hemodialysis patients. Kidney Int 54: 561-569, 1998
9. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998
10. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248, 2005
11. Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360: 1395-1407, 2009
12. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ: Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA 291: 451-459, 2004
13. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C: Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis. Lancet 371: 117-125, 2008
14. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW: Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108: 2154-2169, 2003
15. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M: Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110: 1557-1563, 2004
16. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO: HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61: 297-304, 2002
17. Mason NA, Bailie GR, Satayathum S, Bragg-Gresham JL, Akiba T, Akizawa T, Combe C, Rayner HC, Saito A, Gillespie BW, Young EW: HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 45: 119-126, 2005
18. US Renal Data System: USRDS 2006 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2006
19. Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, Lewis J, Rocco M, Toto R, Windus D, Ornt D, Levey AS: Cardiac diseases in maintenance hemodialysis patients: Results of the HEMO Study. Kidney Int 65: 2380-2389, 2004
20. Baigent C, Landry M: Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 207-210, 2003
21. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS: Prevalence of chronic kidney disease in the United States. JAMA 298: 2038-2047, 2007
22. Attman PO, Samuelsson O, Alaupovic P: Lipoprotein metabolism and renal failure. Am J Kidney Dis 21: 573-592, 1993
23. Hirany S, O'Byrne D, Devaraj S, Jialal I: Remnant-like particle-cholesterol concentrations in patients with type 2 diabetes mellitus and end-stage renal disease. Clin Chem 46: 667-672, 2000
24. Weintraub M, Burstein A, Rassin T, Liron M, Ringel Y, Cabili S, Blum M, Peer G, Iaina A: Severe defect in clearing postprandial chylomicron remnants in dialysis patients. Kidney Int 42: 1247-1252, 1992
25. Kwan BC, Kronenberg F, Beddhu S, Cheung AK: Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 18: 1246-1261, 2007
26. Ellsworth JL, Kraemer FB, Cooper AD: Transport of betavery low density lipoproteins and chylomicron remnants by macrophages is mediated by the low density lipoprotein receptor pathway. J Biol Chem 262: 2316-2325, 1987
27. Cohn JS, Marcoux C, Davignon J: Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. Arterioscler Thromb Vasc Biol 19: 2474-2486, 1999
28. Hodis HN: Triglyceride-rich lipoprotein remnant particles and risk of atherosclerosis. Circulation 99: 2852-2854, 1999
29. Austin MA, Hokanson JE, Edwards KL: Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81: 7B-12B, 1998
30. Hopkins PN, Wu LL, Hunt SC, Brinton EA: Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. J Am Coll Cardiol 45: 1003-1012, 2005
31. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study. Circulation 102: 21-27, 2000
32. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT-A randomized controlled trial. JAMA 285: 1585-1591, 2001
33. Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC: Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int 66: 1123-1130, 2004
34. Bruce C, Chouinard RA Jr, Tall AR: Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. Annu Rev Nutr 18: 297-330, 1998
35. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357: 2109-2122, 2007
36. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM: Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356: 1304-1316, 2007
37. Quaschning T, Schomig M, Keller M, Thiery J, Nauck M, Schollmeyer P, Wanner C, Kramer-Guth A: Non-insulindependent diabetes mellitus and hypertriglyceridemia impair lipoprotein metabolism in chronic hemodialysis patients. J Am Soc Nephrol 10: 332-341, 1999
38. Maggi E, Bellazzi R, Falaschi F, Frattoni A, Perani G, Finardi G, Gazo A, Nai M, Romanini D, Bellomo G: Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis? Kidney Int 45: 876-883, 1994
39. Ok E, Basnakian AG, Apostolov EO, Barri YM, Shah SV: Carbamylated low-density lipoprotein induces death of endothelial cells: A link to atherosclerosis in patients with kidney disease. Kidney Int 68: 173-178, 2005
40. Kronenberg F, Konig P, Neyer U, Auinger M, Pribasnig A, Lang U, Reitinger J, Pinter G, Utermann G, Dieplinger H: Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 6: 110-120, 1995
41. Danesh J, Collins R, Peto R: Lipoprotein (a) and coronary heart disease: Meta-analysis of prospective studies. Circulation 102: 1082-1085, 2000
42. Kronenberg F, Neyer U, Lhotta K, Trenkwalder E, Auinger M, Pribasnig A, Meisl T, Konig P, Dieplinger H: The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol 10: 1027-1036, 1999
43. Longenecker JC, Klag MJ, Marcovina SM, Liu YM, Jaar BG, Powe NR, Fink NE, Levey AS, Coresh J: High lipoprotein (a) levels and small apolipoprotein (a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol 16: 1794-1802, 2005
44. McKenney J: New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 164: 697-705, 2004
45. Superko HR, Krauss RM: Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis 95: 69-76, 1992
46. Ballantyne CM, Corsini A, Davidson MH, Holdaas H, Jacobson TA, Leitersdorf E, Marz W, Reckless JP, Stein EA: Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 163: 553-564, 2003
47. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62: 1524-1538, 2002
48. Islam KN, O'Byrne D, Devaraj S, Palmer B, Grundy SM, Jialal I: Alpha-tocopherol supplementation decreases the oxidative susceptibility of LDL in renal failure patients on dialysis therapy. Atherosclerosis 150: 217-224, 2000
49. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): Randomised placebo-controlled trial. Lancet 356: 1213-1218, 2000
50. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W: The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: A randomized, controlled trial. Circulation 107: 992-995, 2003
51. Mune M, Yukawa S, Kishino M, Otani H, Kimura K, Nishikawa O, Takahashi T, Kodama N, Saika Y, Yamada Y: Effect of vitamin E on lipid metabolism and atherosclerosis in ESRD patients. Kidney Int Suppl 71: S126-S129, 1999